CLOs on the Move

Home Instead

www.homeinstead.com

 
The Home Instead Senior Care® network is the world`s leading provider of personalized in-home care services. We have over 1,100 independently owned and operated franchise offices worldwide that employ compassionate CAREGivers who share our dedication to enhancing the lives of aging adults and their families. Services span the care continuum, from companionship and personal care to specialized Alzheimer`s care and hospice support. Caring for others is part of our DNA, and that includes caring for your career. The Home Instead Senior Care network provides best-in-class training, education, and opportunities for career advancement. It also offers you the opportunity to be ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Andy Chapeau
Director and International Counsel Profile

Similar Companies

Life Line Screening of America

The mission of Life Line Screening is to make people aware of an undetected health problem and encourage them to seek follow up care with their physician. We are dedicated to providing the highest quality preventive screenings at an affordable rate.

Kentucky Clinical Research

Kentucky Clinical Research is a Grayson, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pascal Metrics

Pascal Metrics is the preeminent provider in the healthcare industry of real-time patient safety and clinical improvement services to reduce patient harm and related cost.

Ambulatory Surgical Centres Canada Corporation

Ambulatory Surgical Centres Canada Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.